Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

NCT04730544 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer Metastatic
MSI-H Colorectal Cancer

Interventions

DRUG: Nivolumab 480mg + Ipilimumab
DRUG: Nivolumab 240 mg + Ipilimumab

Sponsor

GERCOR - Multidisciplinary Oncology Cooperative Group

Collaborators

[object Object]